Growing Demagogical Ailments and Related Research is Propelling the Veterinary Dermatology Drug Market

Veterinary dermatology drugs market is anticipated to grow at a CAGR of 9.2% by 2031. The market growth is attributed to the increasing number of severe diseases among animals globally, such as autoimmune skin diseases, parasite skin diseases, dander-related skin disorders, alopecia, and intrinsic skin infections. Additionally, the rising adoption of pets is contributing to the market growth. Furthermore, the market players are actively investing in R&D, which is propelling the market growth. 

Dermatological ailments are of concern in both companion animals and livestock animals. These include parasitic infections, allergic infections, and others. According to a study published in Zagazig Veterinary Journal, in 2022, 485 out of 2225 (21.7%) dogs were reported to have different dermatological disorders with alopecia. Mange was the most common dermatological disorder followed by flea infestation and pruritus. The dermatological disorders were more common in the summer (38.8%), and spring (30.3%), and were less common in the autumn and winter (17.1%& 13.8%) respectively. The canines who suffered the most, around 36.3%, belonged to the age group one year and less. Alopecia was an issue in 59.7% of male dogs and 40.2 %of female canines.

Similarly, in November 2023, MDPI published a study on canine Atopic Dermatitis (cAD), highlighting that around 20–30% of dogs are affected. cAD is the most common primary cause of otitis externa, with incidences ranging from 17 to 80% of cAD cases. Additionally, around 60% of atopic dogs suffer from concomitant allergic conjunctivitis, which is related to eye pruritus and skin lesion scores in the head region. 

Thus, veterinary instructors, market players, researchers, and international organizations are collectively working to address the issues in canines and other animal classes. The major players in the global veterinary dermatology drugs market include Bimeda, Inc., Ceva Sante Animale, Elanco, Merck & Co., Inc., and Zoetis Inc., among others.  The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions, and more. 

Recent Developments 

• In October 2024, Animal Dermatology Group, Inc. acquired four dermatology specialty practices, Long Green Animal Dermatology of Baldwin, MD, Nashville Veterinary Dermatology of Nashville, TN, Animal Dermatology & Allergy of Estero, FL, and Dermatology & Allergy Clinic for Animals of Santa Barbara, CA.

• In October 2024, the FDA approved NexGard® PLUS by Boehringer Ingelheim Animal Health USA, Inc., for dogs. The tablets are aimed at the treatment of Haemaphysalis longicornis (long-horned tick) infestations in dogs and puppies eight weeks of age and older. Additionally, it provides relief against erythema, alopecia, papules, scales, crusts, and excoriation in dogs with flea infestations and signs of Flea Allergy Dermatitis (FAD), following afoxolane.  

• In September 2024,  Elanco Animal Health Inc. announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, as a once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

• In June 2024, the FDA approved Trimeprazine with Prednisolone, by ZyVet Animal Health, Inc.,  for the relief of itching and the reduction of inflammation regardless of cause, for most skin disorders of dogs such as eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular, and nonspecific). It relieves pruritis which does not respond to other therapies. 

• In July 2024, FDA approved MoxiSolv™ Injection by Bimeda Animal Health Ltd., to treat Linognathus vituli and Solenopotes capillatus. It additionally treats Psoroptes ovis.

• In November 2023, a monoclonal antibody therapy, namely Cytopoint, by AVMA (American Veterinary Medical Association) was approved by FDA, to treat seasonal and environmental allergies in dogs. Cytopoint works by binding to and neutralizing the cytokine interleukin 31, the cytokine involved in causing itchiness, inhibiting pruritus, and reducing skin lesions. 

Encapsulating, the increasing dermatological issues among companion animals and livestock, are emerging as a serious concern. The deteriorating environmental conditions, changing climatic conditions, and nutritional deficiencies, stand as the root cause for the skin concerns. Thus, researchers and market players are focusing on developing solutions that can eliminate the concern and provide relief for the veterinarian.